Show all
We are headquartered in Carmiel, Israel.
Protalix Ltd. was established in 1993.

Our headquarters are located at 2 Snunit Street, Science Park, P.O. Box 455, Carmiel 2161401, Israel and we can be contacted at Tel: +972-4-988-9488; Fax: 972-4-988-9489. We also maintain an office at 2 University Plaza, Suite 100, Hackensack, NJ  07601; Tel. +1-201-696-9345.

As of December 31, 2022, we had 197 employees, of whom 17 have an M.D. or a Ph.D. in their respective scientific fields.
Kesselman & Kesselman, Certified Public Accountant (Isr.), a member of PricewaterhouseCoopers International Limited, independent registered public accounting firm. Kesselman & Kesselman is located at Derech Menachem Begin 146, Tel Aviv 6107120, Israel, and can be reached at Tel: +972-3-795-4555 Fax: +972-3-795-4556.
Protalix BioTherapeutics' fiscal year end is December 31.

Information regarding Protalix BioTherapeutics may be obtained through its news releases, presentations and other materials all of which may be accessed directly through this site. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements and other filings with the U.S. Securities and Exchange Commission may be accessed directly through this site or through the U.S. Securities and Exchange Commission at www.sec.gov.

Protalix BioTherapeutics’ legal team is Mayer Brown LLP; they may be reached at +1 (212) 506-2500.

Investor and media inquiries can be directed to: ir@protalix.com or: Chuck Padala, LifeSci Advisors, LLC, Tel +1 (646) 627-8390, chuck@lifesciadvisors.com or Moran Meir Beres, LifeSci Advisors, LLC, Tel +972 (77) 693‑5513, moran@lifesciadvisors.com.

Protalix BioTherapeutics’ transfer agent is American Stock Transfer & Trust Company, LLC. The transfer agent may be reached at +1 (800) 937-5449 or +1 (718) 921-8300. Please see www.astfinancial.com for additional information regarding the transfer agent.

Protalix BioTherapeutics' common stock trades on the NYSE American under the ticker symbol PLX and the CUSIP is 74365A309. Protalix BioTherapeutics’ U.S. ISIN is US74365A3095.

J. Streicher & Co., LLC

As of May 15, 2023, Protalix BioTherapeutics had approximately 67,530,757 shares of its common stock, par value $0.001 per share, outstanding.  This number gives effect to the 1-for-10 reverse stock split that went into effect on December 19, 2019.

No, Protalix BioTherapeutics does not pay a dividend.
Protalix BioTherapeutics currently discloses financial information in its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. Earnings releases are generally issued, and earnings calls are generally held, on the same day financial information is released.

The Protalix BioTherapeutics 2023 Annual Meeting of Stockholders is scheduled for June 28, 2023.

Protalix BioTherapeutics became a U.S. public company through a reverse merger with Orthodontix Inc. on December 31, 2006. On October 25, 2007, Protalix BioTherapeutics issued and sold 10,000,000 shares of common stock in an underwritten public offering at a price of $5.00 per share.
Protalix BioTherapeutics became a U.S. public company through a reverse merger with Orthodontix Inc. on December 31, 2006.